Featured Research

from universities, journals, and other organizations

With no West Nile vaccine in sight, self-protection is key

Date:
September 4, 2012
Source:
University of Alabama at Birmingham
Summary:
As this year's threat from the West Nile virus continues, one infectious diseases expert says a vaccine is not in our near future, so people need to protect themselves.

As this year's threat from the West Nile virus continues, one infectious diseases expert at the University of Alabama at Birmingham says a vaccine is not in our near future, so people need to protect themselves.

The virus, most often spread by the bite of an infected mosquito, can lead to West Nile fever or severe West Nile disease. As of Aug. 28, 2012, WNV infections have been reported in 48 states, with a total of 1,590 cases in people, and 66 deaths, according to the Centers for Disease Control and Prevention.

"West Nile comes and goes," explains Qianjun Li, Ph.D., assistant professor in the Division of Infectious Diseases in the UAB Department of Medicine. "It peaked in Alabama in 2003 with 37 cases and three deaths; in 2007 there were 24 cases and three deaths in Alabama. Now it's back again throughout the United States." The virus "can be a big threat to us and we can't track it because the pattern changes year to year," Li adds.

Li's research focuses on mosquito-transmitted viruses, such as yellow fever, dengue fever and WNV. His main focus is on anti-viral drug discovery, screening for lead compounds or potential drugs to treat these diseases.

"There are human vaccines for WNV in the clinical trial phase, but with the typically low incidence level, it is challenging to get funding to develop these vaccines," Li explains.

Li attributes this year's spike to last year's mild winter. "Those warmer temperatures allowed for the mosquitoes to survive and continue populating into the spring," he says.

WNV can continue spreading into the fall, says the CDC. Without a vaccine available and the mosquitoes here to stay for the time being, David Kimberlin, M.D., UAB professor of pediatrics and president-elect of the Pediatric Infectious Diseases Society, says the best thing you can do is protect yourself.

"Even though most of the cases are coming from six states -- Texas, South Dakota, Mississippi, Oklahoma, Louisiana and Michigan -- people everywhere need to consistently use mosquito repellant containing DEET," Kimberlin explains.

And while this year's WNV incidence is the highest seen since 1999, Kimberlin says it should not be a cause for alarm. "I don't think people should be any more or less concerned because the reporting of cases is increasing -- this is just indicating that we have a more severe season than usual this year."


Story Source:

The above story is based on materials provided by University of Alabama at Birmingham. The original article was written by Nicole Wyatt. Note: Materials may be edited for content and length.


Cite This Page:

University of Alabama at Birmingham. "With no West Nile vaccine in sight, self-protection is key." ScienceDaily. ScienceDaily, 4 September 2012. <www.sciencedaily.com/releases/2012/09/120904151639.htm>.
University of Alabama at Birmingham. (2012, September 4). With no West Nile vaccine in sight, self-protection is key. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2012/09/120904151639.htm
University of Alabama at Birmingham. "With no West Nile vaccine in sight, self-protection is key." ScienceDaily. www.sciencedaily.com/releases/2012/09/120904151639.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins